REFRACTORY ACUTE MYELOID LEUKEMIA
Clinical trials for REFRACTORY ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with tough leukemia: drug combo trial shows promise
Disease control CompletedThis early-stage trial tested a combination of two chemotherapy drugs (CPX-351) and a targeted antibody (GO) in children whose acute myeloid leukemia (AML) had returned or didn't respond to standard treatment. The goal was to find the safest dose and see if the combo could help c…
Matched conditions: REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:07 UTC
-
New combo therapy shows promise for Hard-to-Treat leukemia
Disease control CompletedThis early-stage trial tested the safety and best dose of two drugs (enasidenib and cobimetinib) given together to people whose acute myeloid leukemia (AML) had returned or stopped responding to treatment. Only patients with specific gene mutations (IDH2 and RAS) were included. T…
Matched conditions: REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 02:02 UTC
-
New drug combo shows promise in Tough-to-Treat leukemia
Disease control CompletedThis early-phase study tested two drugs, pevonedistat and decitabine, together in 12 people with high-risk acute myeloid leukemia (AML). The main goal was to find the safest dose and understand side effects. Researchers also looked at whether the combination could help control th…
Matched conditions: REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 02:00 UTC
-
Donor immune cells show promise in Tough-to-Treat leukemia trial
Disease control CompletedThis early-stage trial tested the safety of giving donor natural killer (NK) cells to 19 people with acute myeloid leukemia that had returned or not responded to treatment. The NK cells were grown in a lab and given as an off-the-shelf therapy. The main goal was to find the safes…
Matched conditions: REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: Sumithira Vasu • Aim: Disease control
Last updated May 17, 2026 01:59 UTC
-
Immunotherapy combo shows promise for Post-Transplant blood cancers
Disease control CompletedThis study tested a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 29 adults with high-risk or returning acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after a donor stem cell transplant. The goal was to find the safest dose and see if the dr…
Matched conditions: REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
New Two-Step transplant shows promise for tough blood cancers
Disease control CompletedThis study tested a two-step stem cell transplant for 62 people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor immune cells followed by a stem cell transplant. The goa…
Matched conditions: REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated May 11, 2026 20:38 UTC